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1

Abstract

2

Background: The majority of research performed to date has examined the effects of

3

commonly known antioxidants such as vitamins C, E and A, and carotenoids on age-related

4

macular degeneration (AMD) risk and progression. To date, there is limited research on

5

promising phytochemicals with antioxidant and anti-inflammatory properties, including

6

flavonoids.

7

Objectives: In this exploratory study, we aimed to assess the independent associations

8

between dietary intake of total flavonoids and common flavonoid classes with the prevalence

9

and 15-year incidence of AMD.

10

Design: In this population-based cohort study, 2856 adults aged 49+ years at baseline and

11

2037 followed up 15-years later were included in prevalence and incidence analysis,

12

respectively. Dietary intake was assessed using a semi-quantitative food-frequency

13

questionnaire (FFQ). Estimates of the flavonoid content of foods in the FFQ were assessed

14

using the US Department of Agriculture Flavonoid, Isoflavone and Proanthocyanidin

15

databases. AMD was assessed from retinal photographs.

16

Results: In cross-sectional analysis, each 1-SD increase in total overall flavonoid intake was

17

associated with reduced likelihood of any AMD, multivariable-adjusted OR 0.76 (95% CI

18

0.58, 0.99). Each 1-SD increase in dietary intake of total flavonol and total flavanone was

19

associated with reduced odds of prevalent any AMD: multivariable-adjusted OR 0.75 (95%

20

CI 0.58, 0.97); and OR 0.77 (95% CI 0.60, 0.99), respectively. A marginally significant trend

21

(p=0.05) was observed between increasing intake of total flavanone and hesperidin (from first

22

to fourth quartile) and reduced likelihood of incident late AMD, after multivariable

23

adjustment. Participants who reported one or more serves of oranges per day versus those

24

who never ate oranges at baseline had reduced risk of late AMD 15 years later: multivariable-

25

adjusted OR 0.39 (95% CI 0.18, 0.85).

4

26

Conclusions: Our novel findings suggest an independent and protective association between

27

dietary intake of flavonoids and the likelihood of having AMD. Additional prospective cohort

28

studies are needed to validate these findings.

29
30

Keywords: age-related macular degeneration; flavonoids; Blue Mountains Eye Study;

31

Prevalence; Incidence.
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32

Introduction

33

Age-related macular degeneration (AMD) is the leading cause of blindness and severe visual

34

impairment in older adults (1). Current evidence suggests that AMD patients should be given

35

dietary advice to increase consumption of dark green leafy vegetables, to consume low-

36

glycemic index diets, and to consume fish at least twice a week (2-6). The Age-Related Eye

37

Disease Study (AREDS) demonstrated that taking a supplement containing high doses of

38

vitamin C, vitamin E, beta-carotene, zinc, and copper could reduce AMD progression by 25%

39

(7-12). A follow-up study (AREDS 2), found adding lutein and zeaxanthin (naturally

40

occurring carotenoids) or omega-3 fatty acids to the original AREDS formulation (with beta-

41

carotene) had no overall effect on the risk of late AMD. However, the trial found that

42

replacing beta-carotene with a 5-to-1 mixture of lutein and zeaxanthin could help to further

43

reduce the risk of late AMD, particularly among people who had a low background dietary

44

intake of lutein and zeaxanthin (5,6).

45

The majority of research performed to date has examined the effects of commonly

46

known antioxidants such as vitamins C, E and A, and carotenoids (lutein and zeaxanthin) on

47

AMD risk and progression. There is limited research on promising phytochemicals with

48

antioxidant and anti-inflammatory properties, including flavonoids (13). Flavonoids are

49

bioactive compounds found in foods such as tea, chocolate, red wine, fruit, and vegetables

50

(14). Flavonoids found in foods can be divided into six main flavonoid classes: flavonols,

51

flavan-3-ols, flavones, flavanones, anthocyanins, and isoflavones (14,15). Flavonoids may

52

have antioxidant and anti-inflammatory activities (15,16). There is also strong evidence that

53

flavonoids positively impact vascular health through improved endothelial function (17).

54

Thus, the role of flavonoids seem promising for reversing oxidative stress and inflammation-

55

associated damage and improving vascular function and thus, possibly improving the clinical

56

features of AMD (13).

6

57

However, additional research is needed to establish whether flavonoid intake is

58

beneficially associated with risk of AMD. Hence, we aimed to use a well characterized large

59

cohort of adults aged 49+ years to explore: 1) Associations between dietary intake of total

60

flavonoids with the prevalence and 15-year incidence of AMD (primary endpoints),

61

independent of potential confounders; 2) Prospective relationship between six common

62

flavonoid classes (flavonols, flavan-3-ols, flavones, flavanones, anthocyanins, and

63

isoflavones) and key individual flavonoids (quercetin and hesperidin) with the prevalence and

64

15-year incidence of AMD; and 3) Associations between the main foods and beverages

65

contributing to total flavonoids e.g. tea, apples, oranges and orange juice, and both the

66

prevalence and 15-year incidence of AMD.

67
68

Methods

69

Study population

70

The Blue Mountains Eye Study (BMES) is a population-based cohort study of common eye

71

diseases and other health outcomes in a suburban Australian population located west of

72

Sydney. Study methods and procedures have been described elsewhere (18). Baseline

73

examinations of 3654 residents aged >49 years were conducted during 1992-4 (BMES-1;

74

82.4% participation rate). Selection bias at baseline was minimised after multiple call-back

75

visits, including door-knocking, telephone reminders and letters at recruitment. Surviving

76

baseline participants were invited to attend examinations after 5- (1997-9, BMES-2), 10-

77

(2002-4, BMES-3), and 15 years (2007-9, BMES-4) at which 2334 (75.1% of survivors),

78

1952 participants (75.6% of survivors) and 1149 (55.4% of survivors) were re-examined,

79

respectively. Participants who did not return to the 5-year visit were also invited to the 10- or

80

15-year visits. For the current report we analyzed data from BMES-1 through to BMES-4.

81

The University of Sydney and the Western Sydney Area Human Ethics Committees approved

7

82

the study including all methods that were performed, and written informed consent was

83

obtained from all participants at each examination. All methods in this study were performed

84

in accordance with the relevant guidelines and regulations.

85
86

Assessment of AMD

87

We took two 30° stereoscopic color retinal photographs of the macula of both eyes, which

88

were graded for presence of early and late AMD using the Wisconsin AMD Grading System

89

(19,20). Inter- and intra-grader reliability showed good agreement for grading of specific

90

AMD lesions with quadratic weighted kappa values ranging from 0.64 to 0.93 and 0.54-0.94

91

respectively (21). The detailed methodology of AMD ascertainment in this population has

92

been previously reported (19,20). Early AMD was defined as the absence of late AMD and

93

presence of either: 1) large (>125-µm diameter) indistinct soft or reticular drusen or 2) both

94

large distinct soft drusen and retinal pigmentary abnormalities (hyperpigmentation or

95

hypopigmentation) in either eye (20). Similarly, late AMD was defined as the presence of

96

neovascular AMD or geographic atrophy in either eye (20). Any AMD was defined as having

97

early or late AMD. A retinal specialist (P.M.) adjudicated all uncertain retinal pathology and

98

confirmed all late AMD cases.

99
100

Assessment of flavonoid intake

101

Dietary data were collected using a 145-item self-administered food frequency questionnaire

102

(FFQ). The FFQ is modified for Australian diet and vernacular from an early Willett FFQ

103

(22) and includes reference portion sizes. Participants used a 9-category frequency scale to

104

indicate the usual frequency of consuming individual food items during the past year. Foods

105

listed in the FFQ were categorized into major food categories and subcategories similar to

106

those used for the 1995 Australian National Nutrition Survey (23). Estimates of the flavonoid

8

107

content of foods in the FFQ were derived from the US Department of Agriculture (USDA)

108

Database for the Flavonoid Content of Selected Foods (24), USDA Database for the

109

Isoflavone Content of Selected Foods (25) and USDA Database for the Proanthocyanidin

110

Content of Selected Foods (26).

111

The method of computing the flavonoid content of foods was similar to that outlined in

112

Mink et al. (27) Specifically, for each food, we computed the intake of each individual

113

flavonoid compound present in the food, the sum of assessed flavonoids for each flavonoid

114

class, by summing the individual compounds of each flavonoid class, and the sum of all

115

flavonoid intakes, by summing the flavonoid classes. The flavan-3-ol content of foods was

116

considered to represent the average of total flavan-3-ol and proanthocyanidin monomer

117

contents. For foods where only the flavan-3-ol or proanthocyanidin monomer content was

118

available, the single value provided was used to represent the flavan-3-ol content. The

119

proanthocyanidin content of foods was calculated by summing the proanthocyanidin dimers,

120

trimers, 4–6mers, 7–10mers and polymers. Where multiple varieties of a food listed in the

121

FFQ were reported in the databases, the average flavonoid content of all similar varieties was

122

computed, consistent with the descriptors used in the FFQ output. Foods in the FFQ that were

123

not in the flavonoid databases were assumed to contain no flavonoids. Intakes of flavonoid

124

classes (in mg/d) were calculated by multiplying the estimated intake (g edible portion/d)

125

from the FFQ, with the flavonoid class content (mg/d edible portion) of each food item on the

126

questionnaire. Some of the food items on the FFQ with multiple ingredients (e.g., pizza) were

127

assigned a weighted value on the basis of a USDA standard recipe.

128
129

Assessment of covariates

130

Participants self-reported smoking status as: never smoked; past smoker; or current smoker.

131

We extracted separate data on the frequency of consuming fish (e.g. salmon, tuna and

9

132

sardines) and dietary intakes of lutein and zeaxanthin from the FFQ. The United States

133

Department of Agriculture Carotenoid Food Composition database (28) was used to estimate

134

the intakes of other combined lutein and zeaxanthin. Genotypic status was available for the

135

complement factor H (CFH) single nucleotide polymorphism (SNP) rs1061170 in 2041

136

baseline participants who returned at BMES2 and for the age-related maculopathy

137

susceptibility gene 2 (ARMS2) SNP rs10490924 in 1893 baseline participants who returned at

138

BMES2. Two sources of genotypic information were used (29). TaqMan assays (Applied

139

Biosystems, Foster City, CA), had been performed to provide specific genotyping of

140

rs1061170 in 1925 individuals and rs10490924 in 638 individuals. In addition, BMES

141

genotyping was also carried out for a genome-wide association study (GWAS) using a

142

custom array (Human 670-Quad, version 1, Illumina Inc) at the Wellcome Trust Centre for

143

Human Genetics, Sanger Institute, Cambridge, UK, as part of the Wellcome Trust Case

144

Control Consortium 2. After quality control, genotype imputation was performed using a

145

genetic variation catalogue (1000 Genomes, version 1) and IMPUTE software. Imputed

146

genotypic status was available for rs1061170 in 1657 baseline participants who returned at

147

BMES2 and rs10490924 in 1802 baseline participants who returned at BMES2. This

148

information on genotyping status from imputed data was used where TaqMan assays were

149

not available, for rs1061170 in 116 individuals and for rs10490924 in 1255 individuals.

150

Concordance rates between typed and imputed SNP values were 99.6% for rs1061170 and

151

99.2% for rs10490924. Imputation data metrics were as follows: imputation R2 values were

152

0.968 for rs1061170 and 0.996 for rs10490924, the proportion of the sample with missing

153

SNP information was 8.8% for rs1061170 and 0.5% for rs10490924, Hardy Weinberg

154

equilibrium p values were 0.79 for rs1061170 and 0.95 for rs10490924, minor allele

155

frequencies were 0.39 for rs1061170 and 0.22 for rs10490924.

156
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157

Statistical analysis

158

In exploratory analyses, we assessed associations with the prevalence and 15-year incidence

159

of AMD, which were the primary endpoints. These primary endpoints did not change during

160

the course of the present study or during post-hoc analyses. SAS statistical software (SAS

161

Institute, Cary NC) version 9.4 was used for analyses. Energy-adjusted dietary flavonoid

162

intakes were transformed to normal scores using the Blom method. Associations between

163

energy-adjusted baseline dietary flavonoid intakes (study factor) and prevalence of AMD

164

(study outcome) were examined using logistic regression analysis. Further, associations

165

between energy-adjusted baseline dietary flavonoid intakes and 15-year cumulative incidence

166

of AMD were examined in discrete logistic regression models. The discrete logistic model

167

refers to a survival model in which event times are treated as being genuinely discrete in

168

truth, rather than being on a continuous spectrum. The discrete time hazard is related to

169

covariates by a logistic regression equation (30,31). We have used its implementation in SAS

170

in proc phreg, where a partial likelihood estimation method is used. Findings were also

171

examined after accounting for the competing risk of death using Fine and Gray’s model (32)

172

for cumulative incidence in the presence of competing risks. Regression analysis was first

173

adjusted for age and sex, and then for covariates that have been found to be associated with

174

incidence of AMD in the BMES cohort: current smoking, fish consumption, intakes of lutein

175

and zeaxanthin, and the presence of CFH and ARMS2 SNPs, rs1061170 and rs10490924,

176

respectively. Genotype status was included as an adjustment factor in multivariable-adjusted

177

models using three categories (no minor alleles, one minor allele only, or two minor alleles),

178

based on an additive model for genetic effects. Further adjustments for BMI, hypertension,

179

physical activity (in metabolic equivalents) and dietary vitamin C intake were also considered

180

but did not appreciably change the observed estimates, so were not included in the main

11

181

analysis. Findings from all analyses are expressed as adjusted odds ratios (OR) with 95%

182

confidence intervals (CI).

183
184

Results

185

Prevalence of AMD

186

Of the 3654 subjects examined at baseline, 2856 who had complete dietary data as well as

187

information on AMD lesions were included in the prevalence analysis (Supplemental Figure

188

1). Study characteristics of participants included in cross-sectional analysis are shown in

189

Table 1. At baseline, there were 4.6% and 1.7% participants with early and late AMD,

190

respectively (Table 1). After multivariable-adjustment, each 1-SD increase in intake of total

191

flavonoids was associated with reduced likelihood of any AMD, OR 0.76 (95% CI 0.58,

192

0.99). Each 1-SD increase in intake of total flavonol and total flavanone was associated with

193

reduced odds of any AMD: OR 0.75 (95% CI 0.58, 0.97); and OR 0.77 (95% CI 0.60, 0.99),

194

respectively. Supplementary analysis involved key individual flavonoids - quercetin (a

195

flavonol) and hesperidin (flavanone), and prevalence of AMD. After adjusting for all

196

potential confounders, each 1-SD increase in intake of quercetin was associated with reduced

197

odds of any AMD: OR 0.76 (95% CI 0.58, 0.99). No significant linear associations were

198

observed between hesperidin and prevalence of AMD (data not shown).

199

Table 2 shows the association between quartiles of intake of flavonoids and prevalence

200

of AMD. Participants in the highest quartile of total flavanone intake compared to those in

201

the lowest quartile of intake had reduced odds of any and early AMD. Those in the highest

202

versus lowest quartile of total flavonol intake had a 57% reduced likelihood of any AMD,

203

after multivariable adjustment. Participants in the highest quartile of total hesperidin intake

204

compared to those in the lowest quartile of intake had reduced odds of any and early AMD

205

(Table 2).
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206

Additional analysis involved investigating the main foods and beverages contributing to

207

total flavonoids, flavonols, and flavanones i.e. apples, oranges, tea and orange juice.

208

Compared to participants who did not consume any oranges (reference group), those who

209

reported having one or more serves of oranges per week but less than one serve per day had

210

reduced odds of any AMD: multivariable-adjusted OR 0.42 (95% CI 0.21, 0.84). Similarly,

211

participants who reported one or more serves of oranges per day compared to the reference

212

group had reduced odds of any AMD OR 0.42 (95% CI 0.20, 0.89). Also, compared to

213

participants who did not consume any oranges, participants who ate one or more serves of

214

oranges per week but had less than one serve per day had 92% reduced odds of late AMD:

215

OR 0.08 (95% CI 0.01, 0.76). Participants who consumed one or more serves of orange juice

216

per day compared to those who never consumed orange juice had reduced likelihood of

217

having early AMD: multivariable-adjusted OR 0.35 (95% CI 0.14, 0.85). No significant

218

associations were observed between consumption of apples, tea, red wine and beer with

219

prevalence of AMD (data not shown).

220
221

Incidence of AMD

222

Of the 2856 included in the prevalence analysis, 2037 participants with complete AMD and

223

lifestyle data were re-examined 5, 10 and/or 15 years later (i.e. at least one follow-up

224

examination), and therefore included in incidence analysis (Supplemental Figure 1). Baseline

225

characteristics of participants included in longitudinal analysis are shown in Table 1. There

226

were 15.3% and 4.1% incident early and late AMD cases, respectively. No significant linear

227

associations were observed between flavonoid intake and 15-year incidence of AMD (data

228

not shown). A marginally significant trend was observed between increasing intake of total

229

hesperidin (from first to fourth quartile) and lower 15-year incidence of late AMD, after

230

multivariable adjustment (Table 3). Findings were essentially similar after accounting for the
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231

competing risk of death, except that the trend across quartiles of hesperidin became

232

marginally non-significant (p=0.06), while a significant trend emerged between quartiles of

233

increasing flavonol intake and increased incidence of early AMD (p=0.03). Participants who

234

reported one or more serves of oranges per day versus those who never ate oranges at

235

baseline had reduced risk of incident late AMD 15 years later: multivariable-adjusted OR

236

0.39 (95% CI 0.18, 0.85). No significant associations were observed between consumption of

237

apples, orange juice, tea, red wine and beer with the 15-year incidence of AMD (data not

238

shown).

239
240

Discussion

241

This prospective cohort study of older adults provides novel epidemiological evidence of an

242

independent association between total flavonoid intake as well as the intake of specific

243

flavonoid classes and AMD. Specifically, we observed significant and protective associations

244

between the intake of total flavonoids as well as total flavonol and total flavanone intake with

245

AMD prevalence. Modest associations were also observed between the intakes of total

246

flavone, flavanone and hesperidin and risk of incident late AMD 15 years later. Our study

247

suggests that consumption of oranges (a key contributor to total flavanone) is inversely and

248

independently associated with both prevalence and incidence of late AMD.

249

The median intake of total flavonoids in our cohort was 875 mg/day which is higher

250

than that previously reported in a Western Australia cohort (median intake of 696-mg/d in

251

women aged >75 years) (14) and in an Australia-wide nutrition survey (median intake of 454

252

mg/day in those aged 19+years) (33). This difference is likely to be due to variations in age-

253

distribution, However, variations in food content databases and the different dietary

254

assessment methods administered could also explain the differences in flavonoid intake

255

observed between studies (14).
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256

Higher total overall flavonoid intake and intake of particular flavonoid subgroups e.g.

257

flavonol and flavanone, were associated with reduced odds of having AMD. This observed

258

association is in line with existing evidence, as flavonoids are found in abundance in fruits

259

and vegetables (15) and adequate consumption of fruits and vegetables has been established

260

as being protective against AMD (2,34). Our findings also concur with the existing published

261

literature which has shown that following consumption, flavonoids may contribute to a

262

variety of beneficial biological activities in humans (14). There is robust data now showing

263

that flavonoids can preserve and enhance nitric oxide status and improve endothelial function

264

(35,36). There is also evidence that these compounds can minimize oxidative damage and

265

inflammation (15,16). Moreover, among the known angiogenesis inhibitors, flavonoids seem

266

to play an important role (37). While, the mechanism behind the antiangiogenic effect of

267

flavonoids is unclear, one proposed pathway is through inhibition of protein kinases (2).

268

Overall, these salutary effects of flavonoids may help to explain the influence these dietary

269

compounds might have on AMD pathogenic processes, that is, the inflammatory, oxidative

270

and angiogenic pathways (38).

271

The associations between flavonoid intake and both AMD prevalence and incidence

272

appear to be class dependent. Specifically, participants with higher intakes of flavonol and

273

flavanone had reduced odds of any AMD, while other flavonoid classes such as flavan-3-ols

274

and isoflavone did not show any significant associations with AMD prevalence. Similarly,

275

differential associations with 15-year incidence of AMD were observed e.g. flavone and

276

flavanone intakes were inversely associated with risk of incident AMD while other flavonoid

277

subgroups were not. The varying structures and bioactivities of the different flavonoid

278

classes, as well as the ability to adequately assess intakes from foods could explain the

279

differential associations observed between the individual flavonoid classes and AMD

280

prevalence and incidence (14,39). Indeed, even a minor structural difference in flavonoids
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281

can have a large impact on their bioavailability (40,41). Further studies are needed to confirm

282

our findings and elucidate the influence of total flavonoids and flavonoid subclasses on the

283

development and progression of AMD in older adults.

284

Our findings are promising, as BMES data show for the first time that flavonoids may

285

be useful food compounds in protecting against AMD. Oral bioavailability of flavonoids,

286

however, is known to be limited by poor intrinsic transmembrane diffusion characteristics

287

and poor solubility (42). Moreover, the activity of the flavonoid metabolites is not well

288

established (42). Further research is also needed to establish whether systemic administration

289

of flavonoids will yield much higher and effective concentrations of the parent flavonoids in

290

the ocular tissues and at much lower doses (42). For the time being, it is reasonable that

291

adequate intake of fruits (particularly oranges), vegetables, and beverages (e.g. orange juice)

292

containing flavonoids be recommended to patients, although it is too early to make

293

recommendations on daily flavonoid intakes for prevention of AMD (15). Strengths of this

294

study include its prospective data collection, long-term follow-up of a population-based

295

sample, use of a validated FFQ and careful adjustment for confounders including genetic risk.

296

Hence, our findings are applicable to the general older Australian population and could also

297

be applicable to older adults in other Western countries. Additionally, this study uses high

298

quality stereoscopic retinal photography with validated grading to assess macular conditions,

299

and a detailed side-by-side comparison of the baseline and follow-up photographs to ensure

300

negligible misclassification of incident AMD (4,43,44). However, this study has some

301

noteworthy limitations. First, the database used for the estimation of flavonoid content of

302

foods is based on US data only and therefore this approach might not have accounted for any

303

variation in the flavonoid content of foods found in Australia (40). Second, we cannot

304

discount the effect of residual confounding from unmeasured or unaccounted factors (e.g.

305

inflammatory markers) on observed associations. Finally, the number of participants who
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306

developed incident AMD was small, and this might have reduced power to detect modest

307

associations with flavonoid intake.

308

In summary, we report novel independent associations between dietary intake of total

309

flavonoids, and some of the common flavonoid classes (e.g. flavonol and flavanone) and

310

AMD among older adults. Further, oranges and orange juice, one of the main foods and

311

beverages contributing to total flavanone, is also likely to independently influence risk of

312

AMD. These findings suggest that a habitual diet high in flavonoids could play a role in

313

AMD prevention and progression. These associations, if confirmed in other epidemiological

314

and intervention studies could have important public health implications.
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Table 1. Baseline characteristics of participants involved in prevalence and 15-year incidence
age-related macular degeneration (AMD) analysis
Prevalence

Incidence

(n=2856)

(n=2037)

65.3 (9.3)

63.8 (8.3)

Males

1259 (44.1)

881 (43.3)

Current smokers

393 (14.2)

247 (12.4)

Fish consumption (≥1 serve/ week)

1690 (59.8)

1200 (59.4)

CFH-rs1061170

1077 (60.9)

1051 (60.6)

ARMS2-rs10490924

629 (38.4)

607 (37.9)

Early

130 (4.6)

268 (15.3)

Late

47 (1.7)

84 (4.1)

Characteristics

Age, yrs

Presence of one or two AMD risk
alleles

AMD type

Data is presented as mean (±SD) or n (%) and p-values were obtained using t-tests for
continuous variables and chi-square analyses for categorical data.

24

Table 2. Associations between flavonoid intake and prevalence of age-related macular
degeneration (AMD) in the Blue Mountains Eye Study (n=2856)
Any AMD

Early AMD

Late AMD

(n=177)

(n=130)

(n=47)

Adjusted OR

Adjusted OR

Adjusted OR

(95% CI)

(95% CI)

(95% CI)

1.0 (reference)

1.0 (reference)

1.0 (reference)

2nd quartile (412.4-881.5)

0.63 (0.31, 1.29)

0.51 (0.23, 1.14)

1.37 (0.31, 6.13)

3rd quartile (881.6-1232.3)

0.62 (0.31, 1.24)

0.63 (0.30, 1.32)

0.60 (0.11, 3.10)

4th quartile (≥1232.4)

0.52 (0.25, 1.06)

0.52 (0.24, 1.12)

0.45 (0.08, 2.60)

0.08

0.12

0.25

1.0 (reference)

1.0 (reference)

1.0 (reference)

2nd quartile (18.3-34.6)

0.43 (0.20, 0.90)

0.46 (0.20, 1.07)

0.28 (0.06, 1.28)

3rd quartile (34.6-46.0)

0.70 (0.36, 1.36)

0.82 (0.40, 1.69)

0.33 (0.08, 1.38)

4th quartile (≥46.0)

0.43 (0.21, 0.88)

0.48 (0.22, 1.07)

0.22 (0.04, 1.02)

0.05

0.16

0.05

1.0 (reference)

1.0 (reference)

1.0 (reference)

2nd quartile (9.6-25.1)

0.51 (0.24, 1.06)

0.34 (0.14, 0.83)

1.61 (0.40, 6.50)

3rd quartile (25.2-47.1)

1.01 (0.55, 1.85)

1.05 (0.55, 1.99)

0.84 (0.18, 3.94)

4th quartile (≥47.2)

0.29 (0.13, 0.66)

0.25 (0.10, 0.63)

0.65 (0.10, 4.06)

0.01

0.02

0.46

1.0 (reference)

1.0 (reference)

1.0 (reference)

2nd quartile (12.3-20.8)

0.46 (0.22, 0.99)

0.52 (0.23, 1.18)

0.26 (0.05, 1.48)

3rd quartile (20.8-26.9)

0.73 (0.37, 1.43)

0.76 (0.36, 1.60)

0.65 (0.17, 2.52)

4th quartile (≥26.9)

0.49 (0.24, 1.00)

0.53 (0.24, 1.17)

0.27 (0.05, 1.39)

0.12

0.21

0.20

1.0 (reference)

1.0 (reference)

1.0 (reference)

Flavonoids (mg/day)
All flavonoids1
1st quartile (≤410.6)

P for trend
Total flavonol1
1st quartile (≤18.2)

P for trend
Total flavanone1
1st quartile (≤9.6)

P for trend
Total quercetin
1st quartile (≤12.3)

P for trend
Total hesperidin
1st quartile (≤5.5)
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2nd quartile (5.5-16.0)

0.63 (0.31, 1.26)

0.49 (0.22, 1.09)

1.44 (0.36, 5.85)

3rd quartile (16.0-30.1)

0.76 (0.40, 1.46)

0.78 (0.39, 1.54)

0.76 (0.15, 3.96)

4th quartile (≥30.2)

0.47 (0.23, 0.97)

0.43 (0.19, 0.93)

0.92 (0.18, 4.74)

0.08

0.10

0.70

P for trend

OR – odds ratio; CI – confidence intervals. Bolded values represent significant associations
(p <0.05) in comparison to the reference group.
1
Values were calculated by using logistic regression analyses and were adjusted for age, sex,
current smoking, fish consumption, intakes of lutein and zeaxanthin, and CFH and ARMS2
SNPS (rs1061170 and rs10490924).
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Table 3. Associations between flavonoid intake and 15-year incidence of age-related macular
degeneration (AMD) in the Blue Mountains Eye Study (n=2037)
Early AMD

Late AMD

(n=268)

(n=84)

Adjusted OR

Adjusted OR

(95% CI)

(95% CI)

1.0 (reference)

1.0 (reference)

2nd quartile (413.0-881.5)

1.13 (0.75, 1.71)

0.72 (0.33, 1.58)

3rd quartile (882.0-1232.3)

0.94 (0.62, 1.42)

1.17 (0.60, 2.29)

4th quartile (≥1232.4)

1.22 (0.82, 1.81)

1.00 (0.50, 2.00)

0.35

0.65

1.0 (reference)

1.0 (reference)

2nd quartile (0.7-1.0)

0.97 (0.66, 1.44)

2.36 (1.13, 5.01)

3rd quartile (1.0-1.5)

0.83 (0.56, 1.23)

1.46 (0.66, 3.23)

4th quartile (≥1.5)

0.75 (0.50, 1.11)

1.52 (0.66, 3.49)

0.10

0.97

1.0 (reference)

1.0 (reference)

2nd quartile (9.6-25.1)

0.92 (0.62, 1.38)

1.15 (0.62, 2.11)

3rd quartile (25.2-47.1)

0.97 (0.67, 1.41)

0.69 (0.36, 1.32)

4th quartile (≥47.2)

0.82 (0.55, 1.22)

0.55 (0.27, 1.09)

0.30

0.05

1.0 (reference)

1.0 (reference)

2nd quartile (5.5-16.0)

1.03 (0.69, 1.53)

1.22 (0.65, 2.27)

3rd quartile (16.0-30.1)

1.11 (0.76, 1.62)

0.88 (0.46, 1.68)

4th quartile (≥30.2)

0.85 (0.57, 1.26)

0.54 (0.26, 1.13)

0.32

0.05

Flavonoids (mg/day)
All flavonoids1
1st quartile (≤410.1)

P for trend
Total flavone1
1st quartile (≤0.64)

P for trend
Total flavanone1
1st quartile (≤9.6)

P for trend
Total hesperidin1
1st quartile (≤5.5)

P for trend

OR – odds ratio; CI – confidence intervals. Bolded values represent significant associations
(p <0.05) in comparison to the reference group.
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1

Values were calculated by using discrete logistic regression models and were adjusted for
age, sex, current smoking, fish consumption, intakes of lutein and zeaxanthin, and CFH and
ARMS2 SNPS (rs1061170 and rs10490924).

